CL2020002562A1 - (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. - Google Patents

(divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.

Info

Publication number
CL2020002562A1
CL2020002562A1 CL2020002562A CL2020002562A CL2020002562A1 CL 2020002562 A1 CL2020002562 A1 CL 2020002562A1 CL 2020002562 A CL2020002562 A CL 2020002562A CL 2020002562 A CL2020002562 A CL 2020002562A CL 2020002562 A1 CL2020002562 A1 CL 2020002562A1
Authority
CL
Chile
Prior art keywords
pyridinecarbonyl
derivatives
divisional application
therapeutic uses
compounds
Prior art date
Application number
CL2020002562A
Other languages
English (en)
Inventor
Thierry Bouyssou
Dirk Gottschling
Niklas Heine
Keenan Lana Louise Smith
Michael D Lowe
Hossein Razavi
Christopher Ronald Sarko
Simon Surprenant
Hidenori Takahashi
Michael Robert Turner
Xinyuan Wu
Original Assignee
Hydra Biosciences Llc
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences Llc, Boehringer Ingelheim Int filed Critical Hydra Biosciences Llc
Publication of CL2020002562A1 publication Critical patent/CL2020002562A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos de fórmula (I) y a sales farmacéuticamente aceptables de los<br /> mismos, en la que R1 a R7,A, Y y L son tal como se definen en el presente documento. La invención<br /> también se refiere a composiciones farmacéuticas que comprenden estos compuestos, a métodos<br /> de uso de estos compuestos en el tratamiento de diversas enfermedades y trastornos, <br /> procedimientos para preparar estos compuestos y productos intermedios útiles en estos<br /> procedimientos.
CL2020002562A 2017-10-27 2020-10-02 (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. CL2020002562A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577883P 2017-10-27 2017-10-27
US201862628313P 2018-02-09 2018-02-09

Publications (1)

Publication Number Publication Date
CL2020002562A1 true CL2020002562A1 (es) 2021-01-15

Family

ID=64270818

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020001097A CL2020001097A1 (es) 2017-10-27 2020-04-23 Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CL2020002562A CL2020002562A1 (es) 2017-10-27 2020-10-02 (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020001097A CL2020001097A1 (es) 2017-10-27 2020-04-23 Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.

Country Status (30)

Country Link
US (4) US10889568B2 (es)
EP (2) EP3786160B1 (es)
JP (2) JP7217273B6 (es)
KR (2) KR102724066B1 (es)
CN (1) CN111527078B (es)
AU (2) AU2018355743B2 (es)
CA (1) CA3078769A1 (es)
CL (2) CL2020001097A1 (es)
CY (2) CY1125488T1 (es)
DK (2) DK3700902T3 (es)
ES (2) ES2946274T3 (es)
FI (1) FI3700902T3 (es)
HR (2) HRP20220991T1 (es)
HU (2) HUE059450T2 (es)
IL (2) IL274039B (es)
LT (2) LT3786160T (es)
MX (1) MX387232B (es)
MY (1) MY202126A (es)
PE (1) PE20210154A1 (es)
PH (1) PH12020550503A1 (es)
PL (2) PL3700902T3 (es)
PT (2) PT3700902T (es)
RS (2) RS64271B1 (es)
SA (1) SA520411843B1 (es)
SG (2) SG10202011632RA (es)
SI (2) SI3786160T1 (es)
TW (2) TWI780246B (es)
UA (1) UA128474C2 (es)
WO (1) WO2019081637A1 (es)
ZA (1) ZA202002372B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3700902T3 (fi) * 2017-10-27 2023-05-25 Boehringer Ingelheim Int TRPC6:n inhibiittoreita
EP3752499B1 (en) * 2018-02-15 2024-03-27 Boehringer Ingelheim International GmbH Inhibitors of trpc6
US11370771B2 (en) * 2018-02-16 2022-06-28 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
IL315313A (en) * 2018-08-24 2024-10-01 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
US12156874B2 (en) * 2019-04-12 2024-12-03 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
WO2021079962A1 (ja) * 2019-10-24 2021-04-29 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物
EP4103245B1 (en) 2020-02-11 2026-04-01 Klinikum der Technischen Universität München (TUM Klinikum) Administration of calcium channel trpc6 inhibitors using balloons, stents or other medical devices
AR121846A1 (es) * 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
CN115379841A (zh) * 2020-04-16 2022-11-22 勃林格殷格翰国际有限公司 治疗呼吸系统病症的trpc6抑制剂
CN113105318B (zh) * 2021-02-23 2022-05-20 中山大学 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用
AU2022366192A1 (en) 2021-10-15 2024-02-29 Boehringer Ingelheim International Gmbh Trpc6 inhibitory compounds for treating sepsis
JP2025023360A (ja) * 2021-12-06 2025-02-17 国立大学法人 熊本大学 Ｔｒｐｃ６の発現を抑制する方法
AU2024328580A1 (en) 2023-08-18 2026-02-05 Boehringer Ingelheim International Gmbh Inhibitors of trpc6 for treating focal segmental glomerulosclerosis

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU658134B2 (en) 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
JPH06509069A (ja) 1991-06-27 1994-10-13 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンドおよびその用途
BR9307570A (pt) 1992-12-02 1999-05-25 Pfizer Diéteres de catecol como inibidores seletivos de pdeiv
PL346795A1 (en) 1998-09-22 2002-02-25 Yamanouchi Pharma Co Ltd Cyanophenyl derivatives
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
WO2002008221A2 (en) 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
ATE417038T1 (de) * 2001-06-15 2008-12-15 Astellas Pharma Inc Phenylpyridincarbonyl piperazinderivate
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
DE10222291A1 (de) 2002-05-18 2003-11-27 Schlafhorst & Co W Faserbandzuführeinrichtung
CN1150176C (zh) 2002-05-22 2004-05-19 上海医药工业研究院 芳烷酮哌嗪衍生物及其应用
CA2581745A1 (en) 2004-10-13 2006-04-27 Neurogen Corporation Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
DE102005044814A1 (de) * 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
AR056582A1 (es) 2005-10-28 2007-10-10 Lilly Co Eli COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE
EP1976848A2 (en) 2005-12-21 2008-10-08 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
JP5019768B2 (ja) 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 新規低分子化合物およびその製造方法
EP2137162B1 (en) 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
JP5082538B2 (ja) 2007-03-28 2012-11-28 Ｄｉｃ株式会社 ピペラジン化合物
EP2379524A1 (en) 2008-12-18 2011-10-26 Boehringer Ingelheim International GmbH Serotonin 5-ht2b receptor inhibitors
US20100234603A1 (en) 2009-03-13 2010-09-16 Xin Linghu Process for Making Substituted Aryl Sulfone Intermediates
US20110039850A1 (en) 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
EA201200570A1 (ru) 2009-10-09 2012-11-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
KR20120107962A (ko) 2009-11-18 2012-10-04 노파르티스 아게 고형 종양 및 다른 악성종양의 치료를 위한 방법 및 조성물
KR101939704B1 (ko) 2010-03-01 2019-01-17 지티엑스, 인코포레이티드 암 치료용 화합물
PH12012502112A1 (en) 2010-04-27 2021-06-23 Mitsubishi Tanabe Pharma Corp Novel amide derivative and use thereof as medicine
NZ603876A (en) 2010-05-13 2015-02-27 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
KR101764952B1 (ko) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
JP5800786B2 (ja) 2011-10-26 2015-10-28 田辺三菱製薬株式会社 新規アミド誘導体を有効成分として含有する医薬組成物
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN103360343B (zh) 2012-03-30 2017-04-19 凯惠药业(上海)有限公司 一种哌嗪酰胺类化合物的制备方法
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
TWI642668B (zh) 2013-05-27 2018-12-01 赫孚孟拉羅股份公司 新穎３，４－二氫－２ｈ－異喹啉－１－酮及２，３－二氫異吲哚－１－酮化合物
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
CA2934700A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
WO2015199206A1 (ja) * 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
US20180305334A1 (en) 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
CN107176927B (zh) 2016-03-12 2020-02-18 福建金乐医药科技有限公司 组蛋白去甲基化酶lsd1抑制剂
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
AU2017282659A1 (en) 2016-06-20 2019-02-07 Rutgers, The State University Of New Jersey Therapeutic compounds
CN107540636A (zh) 2016-06-29 2018-01-05 成都贝斯凯瑞生物科技有限公司 一种含氮杂环衍生物及其应用
CN106317050B (zh) * 2016-08-24 2018-11-23 烟台大学 一种苯基噻唑衍生物及其制备方法与应用
JPWO2018159827A1 (ja) 2017-03-03 2020-01-09 国立大学法人京都大学 植物ステロイドホルモン（ブラシノライド）様活性をもつ非ステロイド化合物の創製
TW201902875A (zh) 2017-03-15 2019-01-16 美商亞瑟尼克斯公司 聯芳基哌啶醯胺化合物及其使用方法
FI3700902T3 (fi) 2017-10-27 2023-05-25 Boehringer Ingelheim Int TRPC6:n inhibiittoreita
CN111491938B (zh) * 2017-11-16 2024-05-24 普林斯匹亚生物制药公司 免疫蛋白酶体抑制剂
EP3752499B1 (en) 2018-02-15 2024-03-27 Boehringer Ingelheim International GmbH Inhibitors of trpc6
US11370771B2 (en) 2018-02-16 2022-06-28 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6

Also Published As

Publication number Publication date
USRE49699E1 (en) 2023-10-17
PL3700902T3 (pl) 2023-09-04
RS63535B1 (sr) 2022-09-30
ES2924933T3 (es) 2022-10-11
DK3700902T3 (en) 2023-05-22
KR20200125758A (ko) 2020-11-04
CY1126109T1 (el) 2023-11-15
EP3700902B1 (en) 2023-03-08
ES2946274T3 (es) 2023-07-14
IL274039A (en) 2020-06-30
LT3786160T (lt) 2022-09-26
US10800757B2 (en) 2020-10-13
AU2018355743B2 (en) 2022-04-14
WO2019081637A1 (en) 2019-05-02
DK3786160T3 (da) 2022-08-22
RS64271B1 (sr) 2023-07-31
AU2018355743A1 (en) 2020-05-14
EP3700902B8 (en) 2023-08-02
CY1125488T1 (el) 2026-02-25
CL2020001097A1 (es) 2020-08-28
US20210163449A1 (en) 2021-06-03
EP3786160A1 (en) 2021-03-03
CN111527078A (zh) 2020-08-11
BR112020007818A2 (pt) 2020-10-20
US10889568B2 (en) 2021-01-12
LT3700902T (lt) 2023-06-26
HUE059450T2 (hu) 2022-11-28
TW201930294A (zh) 2019-08-01
US20190169167A1 (en) 2019-06-06
EP3700902A1 (en) 2020-09-02
HUE062460T2 (hu) 2023-11-28
HRP20220991T1 (hr) 2022-11-11
IL277493B (en) 2022-02-01
UA128474C2 (uk) 2024-07-24
FI3700902T3 (fi) 2023-05-25
ZA202002372B (en) 2023-10-25
MX387232B (es) 2025-03-18
KR20200095467A (ko) 2020-08-10
MY202126A (en) 2024-04-05
PT3700902T (pt) 2023-05-30
NZ763816A (en) 2025-10-31
CN111527078B (zh) 2023-06-02
TWI780246B (zh) 2022-10-11
KR102724066B1 (ko) 2024-10-30
PE20210154A1 (es) 2021-01-26
SG10202011632RA (en) 2021-01-28
MX2020004283A (es) 2021-10-21
SI3700902T1 (sl) 2023-10-30
SA520411843B1 (ar) 2024-01-27
SI3786160T1 (sl) 2022-11-30
JP6979502B2 (ja) 2021-12-15
IL277493A (en) 2020-11-30
JP2021500390A (ja) 2021-01-07
PT3786160T (pt) 2022-08-19
JP7217273B2 (ja) 2023-02-02
JP2021008503A (ja) 2021-01-28
IL274039B (en) 2021-08-31
AU2020250185A1 (en) 2020-11-12
EP3786160B1 (en) 2022-07-13
PH12020550503A1 (en) 2021-03-22
CA3078769A1 (en) 2019-05-02
PL3786160T3 (pl) 2022-10-24
TW202120494A (zh) 2021-06-01
HRP20230502T1 (hr) 2023-09-15
US20190169168A1 (en) 2019-06-06
JP7217273B6 (ja) 2024-02-08
AU2020250185B2 (en) 2022-04-14
SG11202003367TA (en) 2020-05-28
TWI780511B (zh) 2022-10-11

Similar Documents

Publication Publication Date Title
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY37900A (es) Nuevos derivados de rapamicina
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
CR20180232A (es) Macrociclos peptídicos contra acinetobacter baumannii
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX359882B (es) Amidas como moduladores de canales de sodio.
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
MX2020005738A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
PE20211548A1 (es) Compuesto de triazina y su uso para fines medicos
CO7280475A2 (es) Derivados de azaindol que actuan como inhibidores de pi3k
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
MX2020003993A (es) Derivados de bencimidazol y sus usos.
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CY1120608T1 (el) Φαρμακευτικως δραστικες ενωσεις
CO2020005885A2 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2
JOP20200079A1 (ar) مثبطات مستقبل عامل نمو البشرة
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
ECSP18056196A (es) Derivados de indano